Company profile
Revolution Medicines, Inc.
NASDAQ:RVMDBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Daraxonrasib | approved | — | 13 | approved |
| Vociprotafib | phase2 | — | 4 | active |
| Elironrasib | phase1_2 | — | 2 | active |
| Zoldonrasib | phase1_2 | — | 4 | active |
| RMC-5552 | phase1 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05054725 | phase2 | completed | 2021-12-30 | 2024-07-03 | Revolution Medicines, Inc. | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies |
| NCT05462717 | phase1 | active_not_recruiting | 2022-09-19 | 2027-03-31 | Revolution Medicines, Inc. | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors |
| NCT03634982 | phase1 | unknown | 2018-09-28 | 2023-03-31 | Revolution Medicines, Inc. | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors |
| NCT04774952 | phase1 | completed | 2021-04-07 | 2024-05-06 | Revolution Medicines, Inc. | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors |
| NCT03989115 | phase1_2 | completed | 2019-07-02 | 2022-02-08 | Revolution Medicines, Inc. | Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 220910 | NDA | REVOLUTION MEDICINES INC | ||||
Loading… | ||||||